What one share of Kyntra Bio holds
Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia.
Kyntra Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | $45.27 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$9.41 |
| Cash and investments | $12.51 |
| Book value | −$7.44 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | $193.71 | −$28.33 | $12.90 | $36.24 | — | −$115.34 |
| 2014 | $183.22 | −$79.23 | $10.81 | $19.04 | — | — |
| 2015 | $74.92 | −$35.54 | $0.82 | −$8.51 | — | $71.61 |
| 2016 | $72.99 | −$23.14 | $0.50 | $2.33 | — | $61.19 |
| 2017 | $44.87 | −$41.40 | $2.91 | −$25.69 | — | $160.15 |
| 2018 | $63.33 | −$25.70 | $2.39 | −$25.03 | — | $149.01 |
| 2019 | $74.04 | −$22.21 | $1.66 | −$24.37 | — | $147.20 |
| 2020 | $49.06 | −$52.67 | $1.11 | $21.59 | — | $115.42 |
| 2021 | $63.70 | −$78.51 | $1.40 | −$23.67 | — | $56.29 |
| 2022 | $37.60 | −$78.45 | $1.00 | −$39.98 | — | −$5.69 |
| 2023 | $12.03 | −$73.03 | $0.65 | −$81.59 | — | −$51.68 |
| 2024 | $7.40 | −$11.89 | $0.07 | −$34.55 | — | −$55.88 |
| 2025 | $1.59 | $45.38 | $0.01 | −$1.19 | — | −$7.42 |
Common questions about Kyntra Bio
How much does one share of Kyntra Bio earn?
Over the last 12 months, each share of Kyntra Bio earned $45.27 of profit.
Does Kyntra Bio pay a dividend?
Kyntra Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Kyntra Bio’s book value per share?
Kyntra Bio’s book value is negative (−$7.44 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Kyntra Bio have?
Each share of Kyntra Bio has $12.51 of cash and investments, as of June 30, 2026.
What is Kyntra Bio’s free cash flow per share?
−$9.41 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Kyntra Bio bought back shares?
Kyntra Bio’s share count rose about 667% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.